ShiftLeft to Present at No Hat Conference 2021
17.11.2021 11:00:00 EET | Business Wire | Press release
ShiftLeft, Inc., an innovator in automated application security testing, today announced that its Chief Scientist, Fabian Yamaguchi, and Security Research Engineer, Claudiu-Vlad Ursache, will give a presentation focused on Ghidra2cpg at the No Hat Conference in Bergamo, Italy on November 20, 2021. The No Hat 2021 is a security conference organized to bring together specialists, professionals and hobbyists operating in the field of computer security and privacy.
Event Details:
Who: Fabian Yamaguchi, Chief Scientist and Claudiu-Vlad Ursache, Security Research Engineer, ShiftLeft
What: Virtual Session: Presentation on Ghidra2cpg: From graph queries to vulnerabilities in binary code
When: Saturday, November 20, 2021, 11:15am – 12:00pm CET
Where: Centro Congressi Giovanni XXIII - Bergamo, Italy
For more information, visit: https://www.nohat.it/program
Session Abstract - Ghidra2cpg: From graph queries to vulnerabilities in binary code
Uncovering bugs in source code is hard enough as it is, but when all you have is a binary, the importance of tooling becomes undeniable. Disassemblers such as IDA Pro, Ghidra, BinaryNinja or Radare2 provide a strong foundation for an investigation but are designed primarily to assist in what remains a manual investigation. This leaves room for partial automations that make the discovery process less painful.
Fabian and Claudiu were looking to design a search tool for binary code that allows them to uncover instances of programming patterns linked to vulnerabilities - at scale and for multiple major instruction sets. In this talk, they will present ghidra2cpg, an extension for the open-source code mining platform Joern that enables it to process binary code. Together, Joern and ghidra2cpg enable you to quickly uncover the attack surface, search for variants of known vulnerabilities, and gather information interactively using a query language.
In this session they will show how to write queries for the system that describe bugs in source code and introduce corresponding queries for binary code, highlighting what's harder and what is easier to describe when looking at the machine code directly. They will also be looking at modern consumer-grade router firmware and may drop a zero-day or two in the process.
About Fabian Yamaguchi
Fabian is Chief Scientist at ShiftLeft Inc and an Associate Professor Extraordinary at Stellenbosch University. He has over 15 years of experience in the security domain, where he has worked as a security consultant and researcher, focusing on manual and automated vulnerability discovery. Throughout his work, he has identified previously unknown vulnerabilities in popular system components and applications such as the Microsoft Windows kernel, the Linux kernel, the Squid proxy server, and the VLC media player. He has presented his findings and techniques at both major industry conferences such as BlackHat USA, DefCon, First, and CCC, and renowned academic security conferences such as ACSAC, Security and Privacy, and CCS. He holds a master’s degree in computer engineering from Technical University Berlin, as well as a PhD in computer science from the University of Goettingen.
About Claudiu-Vlad Ursache
Claudiu-Vlad Ursache is a Security Research Engineer at ShiftLeft, having recently entered cybersecurity after a decade of writing software. In his day-to-day job he builds static analysis tools and his current research focuses on IoT firmware.
About ShiftLeft
ShiftLeft enables software developers and application security teams to radically reduce the attackability of their applications by providing near-instantaneous security feedback on software code during every pull request. By analyzing application context and data flows in near real-time with industry leading accuracy, ShiftLeft empowers developers and appsec team to find and fix the most serious vulnerabilities faster. Using its patented graph analysis that combines code attributes and analyzes actual attack paths based on real application architecture, ShiftLeft’s platform scans for attack context and pathways typical of modern applications, across APIs, OSS, internal microservices and first-party business logic code, and then provides detailed guidance on risk remediation within existing development workflows and tooling. ShiftLeft CORE, a unified code security platform, combines the company’s flagship NextGen Static Analysis (NG SAST), Intelligent Software Composition Analysis (SCA), and contextual security training through ShiftLeft Educate to provide developers and application security teams the fastest, most accurate, most relevant, and easiest to use automated application security and code analysis platform.
Backed by Bain Capital Ventures, Mayfield, Thomvest Ventures, and SineWave Ventures, ShiftLeft is based in Santa Clara, CA. To learn how ShiftLeft keeps AppSec in sync with the rapid pace of DevOps, see https://www.shiftleft.io/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005403/en/
Contact information
PR:
Corinna Krueger
ShiftLeft
ckrueger@shiftleft.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
